To review the outcomes of patients with hemoptysis (coughing up blood) treated by embolization with 150–250 µm PVA particles.
Key Findings:
BAE with 150–250 µm PVA particles is effective in controlling hemoptysis, with statistical significance.
Technical success achieved in catheterizing and embolizing hypertrophied bronchial arteries and NBSAs.
Clinical success defined as cessation of hemoptysis or significant reduction in blood loss, with supporting data.
Interpretation:
The use of smaller particles for BAE may provide better outcomes in terms of persistent or recurrent hemoptysis, challenging current opinions on particle size, supported by recent studies.
Limitations:
Retrospective design may introduce bias, affecting the reliability of outcomes.
Single-center study limits generalizability of findings, suggesting the need for multi-center trials.
Conclusion:
BAE using 150–250 µm PVA particles is a safe and effective treatment for hemoptysis, with favorable outcomes and manageable complications, highlighting the need for reevaluation of current practices.
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
